×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
I am seeing a 52 year old, CP-CML. NGS normal. At time of presentation had a mammogram which demonstrated an enlarged LN. Biopsy from LN showed mature neutrophils and involvement by CML. No blasts. Started asciminib. Would you do anything different?
Was the lymph node surgically excised, or was the diagnosis made via needle biopsy?
Was a PET scan performed to assess for hypermetabolic activity both at the site and elsewhere?
I would have considered consulting with radiation oncology to evaluate the potential role of local radiotherapy to the involved node or field.
Other than that, to my knowledge, there is limited data regarding the efficacy of asciminib in extramedullary disease. However, I agree that in a relatively young patient with an unusual site of extramedullary involvement, using a potent and novel agent like asciminib is a reasonable approach.
An alternative consideration could have been dasatinib, given its known activity in extramedullary sites and in blast phase CML. If this lymph node involvement is interpreted as a myeloid sarcoma, would that reclassify the disease as being in blast phase? This point might warrant further discussion.
I believe that the choice of the drug is correct if the patient is in CP. I suggest only a close follow-up of all the superficial LN during the treatment.
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy